We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ovintiv (OVV) Q1 Earnings Meet Estimates, Sales Beat Mark
Read MoreHide Full Article
Ovintiv Inc. (OVV - Free Report) recently reported first-quarter 2021 adjusted earnings per share of $1.10, meeting the Zacks Consensus Estimate. The bottom-line result can be attributed to higher gas price realization and successful cost-control initiatives, partially offset by lower production and oil price realizations.
Meanwhile, the reported figure was higher than the year-ago bottom line of 10 cents per share.
Total revenues of $1.84 billion beat the Zacks Consensus Estimate of $1.65 billion but dropped 30.4% from the year-ago sales of $2.64 billion.
Production and Prices
Total first-quarter production came in at 538,300 barrels of oil equivalent per day (BOE/d) compared with 571,300 BOE/d in the prior-year period. The decline in volumes was in response to the winter storms in Texas and Oklahoma. Natural gas production marginally rose year over year to 1,576 million cubic feet per day while liquids production was down 11.03% to 275,600 BOE/d.
Ovintiv's realized natural gas price was $3.10 per thousand cubic feet compared with the year-ago level of $1.97. Realized oil price decreased to $47.44 per barrel from $48.99 in the first quarter of 2020.
Costs, Capex and Balance Sheet
Total expenses decreased to $1.64 billion from the year-ago figure of $1.88 billion. This decline is primarily attributed to lower depreciation and amortization charges.
Ovintiv’s cash from operating activities in the quarter under review summed $827 million, up from the year-ago figure of $566 million. The company's capital investments were $350 million compared with $790 million in the year-ago period.
As of Mar 31, Ovintiv had cash and cash equivalents worth $9 million, and a long-term debt of $6.4 billion. Its debt-to-capitalization ratio was 60.8.
The company generated non-GAAP free cash flow of $540 million.
Ovintiv’s board of directors declared a quarterly dividend of 9.375 cents per share to its common shareholders of record on Jun 15, 2021, which will be paid out on Jun 30.
Ovintiv, formerly known as Encana Corp., recently concluded the divestment of its Duvernay assets for nearly $263 million comprising approximately $12 million worth contingency payments based on future commodity prices. Proceeds from the sale will be used for debt repayment.
Guidance
Ovintiv reaffirms its 2021 capital expenditure to be $1.5 billion. Following the asset sales, the company now projects crude oil and condensate volumes to average 190,000 barrels per day (bpd) in 2021 compared with its prior guidance of 200,000 bpd.
Zacks Rank & Key Picks
Ovintiv currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the energy space are Whiting Petroleum Corporation , Diamondback Energy, Inc. (FANG - Free Report) and Continental Resources, Inc. , each presently flaunting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Ovintiv (OVV) Q1 Earnings Meet Estimates, Sales Beat Mark
Ovintiv Inc. (OVV - Free Report) recently reported first-quarter 2021 adjusted earnings per share of $1.10, meeting the Zacks Consensus Estimate. The bottom-line result can be attributed to higher gas price realization and successful cost-control initiatives, partially offset by lower production and oil price realizations.
Meanwhile, the reported figure was higher than the year-ago bottom line of 10 cents per share.
Total revenues of $1.84 billion beat the Zacks Consensus Estimate of $1.65 billion but dropped 30.4% from the year-ago sales of $2.64 billion.
Production and Prices
Total first-quarter production came in at 538,300 barrels of oil equivalent per day (BOE/d) compared with 571,300 BOE/d in the prior-year period. The decline in volumes was in response to the winter storms in Texas and Oklahoma. Natural gas production marginally rose year over year to 1,576 million cubic feet per day while liquids production was down 11.03% to 275,600 BOE/d.
Ovintiv's realized natural gas price was $3.10 per thousand cubic feet compared with the year-ago level of $1.97. Realized oil price decreased to $47.44 per barrel from $48.99 in the first quarter of 2020.
Costs, Capex and Balance Sheet
Total expenses decreased to $1.64 billion from the year-ago figure of $1.88 billion. This decline is primarily attributed to lower depreciation and amortization charges.
Ovintiv’s cash from operating activities in the quarter under review summed $827 million, up from the year-ago figure of $566 million. The company's capital investments were $350 million compared with $790 million in the year-ago period.
As of Mar 31, Ovintiv had cash and cash equivalents worth $9 million, and a long-term debt of $6.4 billion. Its debt-to-capitalization ratio was 60.8.
The company generated non-GAAP free cash flow of $540 million.
Ovintiv’s board of directors declared a quarterly dividend of 9.375 cents per share to its common shareholders of record on Jun 15, 2021, which will be paid out on Jun 30.
Ovintiv Inc. Price, Consensus and EPS Surprise
Ovintiv Inc. price-consensus-eps-surprise-chart | Ovintiv Inc. Quote
Update on Duvernay Asset Sales
Ovintiv, formerly known as Encana Corp., recently concluded the divestment of its Duvernay assets for nearly $263 million comprising approximately $12 million worth contingency payments based on future commodity prices. Proceeds from the sale will be used for debt repayment.
Guidance
Ovintiv reaffirms its 2021 capital expenditure to be $1.5 billion. Following the asset sales, the company now projects crude oil and condensate volumes to average 190,000 barrels per day (bpd) in 2021 compared with its prior guidance of 200,000 bpd.
Zacks Rank & Key Picks
Ovintiv currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the energy space are Whiting Petroleum Corporation , Diamondback Energy, Inc. (FANG - Free Report) and Continental Resources, Inc. , each presently flaunting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>